Company intelligence / Profile preview

Saman daroo 8 Pharmaceutical Company

Mashhad, Razavi Khorasan, Iran

Ownership: Private
Development stage: Other

Overview

Saman Darou 8 is a leading Iranian biopharmaceutical company focused on the development and production of high-tech recombinant proteins. The company is most notable for producing Safacto, the first recombinant Factor VIII (rFVIII) developed in Iran and the Middle East for the treatment of Hemophilia A. By leveraging advanced mammalian cell culture and recombinant DNA technology, the company aims to provide affordable and high-quality alternatives to plasma-derived products. Saman Darou 8 operates state-of-the-art GMP-certified manufacturing facilities in Mashhad and plays a critical role in the regional supply chain for essential hematology treatments.

Therapeutic areas: Hematology
Modalities: Recombinant proteinBiologic
Industry: Pharma

Beyond the preview

Go deeper on Saman daroo 8 Pharmaceutical Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saman daroo 8 Pharmaceutical Company.

Explore the full profile